VitaDX is proud to announce that the abstract of its first clinical trial VISIOCYT 1 has been selected at ASCO 2022

VitaDX is proud to announce that the abstract of its first clinical trial "VISIOCYT 1: Artificial Intelligence for the Diagnosis of Urothelial Bladder Carcinoma" has been selected for presentation at ASCO 2022.